Pharyngeal Cancer: Types, Causes, Symptoms, and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Pharyngeal cancer refers to malignancies arising in the pharynx — the hollow tube that runs from the back of the nose to the top of the esophagus. It is divided into three anatomical subsites: the nasopharynx (behind the nasal cavity), the oropharynx (back of the throat, soft palate, tonsils, and base of tongue), and the hypopharynx (below the oropharynx, surrounding the larynx). The vast majority are squamous cell carcinomas, though nasopharyngeal carcinoma frequently has an undifferentiated or non-keratinizing variant with distinct biological behavior. Pharyngeal cancers collectively account for a significant burden of head and neck malignancy worldwide. Nasopharyngeal carcinoma is particularly prevalent in Southeast Asia, southern China, and North Africa, where Epstein-Barr virus (EBV) infection is a dominant etiological factor. Oropharyngeal cancers in Western countries are now predominantly HPV-related, with HPV-positive disease having a considerably better prognosis than HPV-negative, tobacco-driven cancer.

The etiology differs by subsite. Nasopharyngeal carcinoma is strongly associated with Epstein-Barr virus (EBV) infection — EBV DNA is detectable in nearly all cases of WHO type II and III NPC — along with genetic susceptibility in populations of Southeast Asian ancestry, nitrosamine-rich salted fish consumption, and family history. Oropharyngeal cancer has two distinct etiological pathways: HPV-related (predominantly HPV-16 in tonsil and base of tongue cancers, rising steeply in Western countries, predominantly in younger non-smoking patients) and tobacco/alcohol-driven (associated with mutually synergistic use of smoking and heavy alcohol, more common globally). Hypopharyngeal cancer is strongly associated with tobacco smoking, alcohol use, and Plummer-Vinson syndrome (iron-deficiency dysphagia with esophageal web). Occupational exposure to nickel compounds increases nasopharyngeal risk. Overall, tobacco and alcohol account for approximately 75% of all head and neck squamous cell carcinomas.

Symptoms vary by pharyngeal subsite. Nasopharyngeal carcinoma classically presents with painless unilateral neck lymphadenopathy (the most common initial symptom), unilateral nasal obstruction, epistaxis, and unilateral serous otitis media due to Eustachian tube dysfunction. Cranial nerve palsies — particularly CN VI (diplopia), CN V (facial numbness), and CN XII — may occur in locally advanced disease. Oropharyngeal cancer presents with a persistent sore throat, dysphagia, odynophagia (painful swallowing), voice change (muffled 'hot potato' voice), unilateral otalgia (referred ear pain), and neck mass from nodal metastasis. Hypopharyngeal cancer typically presents late with progressive dysphagia, odynophagia, hoarseness (from laryngeal involvement), hemoptysis, and weight loss — often at an advanced stage due to lack of early symptoms. Any neck mass persisting for more than two to three weeks in an adult warrants immediate evaluation.

Evaluation involves endoscopy, imaging, and tissue biopsy. Nasendoscopy allows direct visualization and biopsy of nasopharyngeal lesions; biopsies of neck nodes can confirm metastatic disease. MRI is the preferred modality for soft tissue delineation and skull base involvement in NPC; CT with contrast characterizes nodal disease and cortical bone involvement. PET-CT is essential for staging and detecting occult distant metastases (lung, bone, liver). Staging follows AJCC 8th edition criteria for each subsite. In oropharyngeal cancer, p16 immunohistochemistry (surrogate marker for HPV) is mandatory — HPV-positive and HPV-negative oropharyngeal cancers are now staged separately due to different prognostic implications. Plasma EBV DNA (cell-free EBV DNA) is a highly sensitive and specific biomarker for NPC, used at diagnosis and for post-treatment surveillance. Histopathology of biopsy specimens confirms squamous cell carcinoma type and degree of differentiation. Nutritional assessment is important as dysphagia often leads to significant pre-treatment malnutrition.

Treatment is multidisciplinary, involving head and neck surgeons, radiation oncologists, and medical oncologists. Concurrent cisplatin-based chemoradiation (CRT) is the backbone of treatment for locally advanced pharyngeal cancers. For nasopharyngeal carcinoma, induction chemotherapy with TPF (docetaxel, cisplatin, fluorouracil) or GP (gemcitabine, cisplatin) followed by concurrent CRT is now preferred for stage III–IV disease, based on the GEM20110714 and SYSUCC-002 trials. IMRT (intensity-modulated radiotherapy) to doses of 70 Gy in 35 fractions is standard. For oropharyngeal cancer, transoral robotic surgery (TORS) or transoral laser microsurgery has emerged as an organ-preserving surgical alternative for select HPV-positive T1–T2 tumors, with post-operative radiotherapy or chemoradiation based on pathological risk factors. Hypopharyngeal cancer management often requires total laryngopharyngectomy or larynx-preservation protocol (induction chemotherapy followed by definitive CRT, reserving surgery for non-responders — EORTC 24891 paradigm). Immune checkpoint inhibitors — pembrolizumab and nivolumab — are approved for recurrent/metastatic disease. Targeted therapy with cetuximab (EGFR inhibitor) is used in platinum-ineligible patients.

The prognosis of pharyngeal cancer varies significantly by subsite and HPV/EBV status. Nasopharyngeal carcinoma (NPC) treated with intensity-modulated radiotherapy and concurrent cisplatin achieves 5-year overall survival rates of over 90% for stage I–II disease and 70–80% for stage III–IVA disease with modern induction chemotherapy plus chemoradiation protocols. Plasma EBV DNA normalization after treatment is a highly favorable prognostic marker for durable remission. HPV-positive oropharyngeal cancer has a dramatically better outlook than HPV-negative disease — 5-year overall survival exceeds 80–85% for most HPV-positive patients treated with standard chemoradiation, even with significant nodal burden, compared to 40–50% for HPV-negative, tobacco-driven oropharyngeal cancers. This survival differential has prompted multiple ongoing de-escalation clinical trials for HPV-positive patients (PATHOS, OPTIMA, De-ESCALaTE). Hypopharyngeal cancer carries the worst prognosis among pharyngeal subsites, with 5-year survival rates of only 20–35% for locally advanced disease, reflecting late presentation and aggressive biological behavior. Key prognostic factors across all subsites include tumor stage, nodal involvement, HPV or EBV status, performance status, and response to initial chemotherapy. Long-term monitoring for recurrence using PET-CT and plasma EBV DNA, combined with surveillance for thyroid function, salivary gland function, and swallowing, is essential for all survivors.

HPV vaccination (Gardasil 9) against high-risk HPV types including HPV-16 and HPV-18 is the most important preventive measure for oropharyngeal cancer. Vaccination is most effective when administered before sexual debut and is recommended up to age 26 (and may be considered up to age 45 by shared decision). Tobacco cessation and alcohol abstinence significantly reduce risk of tobacco/alcohol-driven pharyngeal cancers — these factors account for the majority of hypopharyngeal and some oropharyngeal cancers. Reduction in consumption of nitrosamine-rich salt-preserved foods (particularly in high-risk NPC populations) may lower risk. EBV-directed vaccine development is ongoing but no licensed EBV vaccine is currently available. Plasma EBV DNA screening has shown promise as an NPC early detection tool in high-incidence populations in Hong Kong and southern China.

Any painless neck lump persisting for more than two to three weeks in an adult requires urgent referral to a head and neck specialist — this is the most common presentation of pharyngeal cancer with nodal metastasis. Persistent sore throat lasting more than three to four weeks, progressive dysphagia or odynophagia, hoarseness lasting more than three weeks, unexplained otalgia, recurrent epistaxis, or nasal obstruction accompanied by hearing changes all warrant prompt ENT evaluation. Unilateral serous otitis media in an adult without prior history of middle ear disease must be investigated for nasopharyngeal pathology. Unexplained weight loss, especially when combined with dysphagia or voice change, is a red flag for hypopharyngeal cancer. Oropharyngeal ulcers or growths that do not resolve within three weeks need biopsy. Early referral dramatically improves treatment outcomes and functional preservation.